Jupiter Topco LLC Takes $10.64 Million Position in Moderna, Inc. $MRNA

Jupiter Topco LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 151,972 shares of the company’s stock, valued at approximately $10,639,000.

Other large investors have also modified their holdings of the company. MUFG Securities EMEA plc bought a new position in Moderna in the 2nd quarter worth $28,000. Allied Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter valued at about $30,000. Canton Hathaway LLC acquired a new stake in shares of Moderna in the first quarter valued at about $31,000. EverSource Wealth Advisors LLC increased its stake in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the period. Finally, Assetmark Inc. increased its stake in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares during the period. 75.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the subject of several recent analyst reports. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday. The Goldman Sachs Group raised their price objective on shares of Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 19th. UBS Group boosted their price objective on shares of Moderna from $50.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 20th. Argus raised shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Friday. Finally, Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $80.53.

Moderna Stock Performance

NASDAQ MRNA opened at $137.99 on Friday. The stock has a market cap of $55.09 billion, a P/E ratio of -17.27 and a beta of 0.91. The company’s 50-day simple moving average is $77.11 and its 200 day simple moving average is $59.73. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned ($2.13) earnings per share. As a group, research analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares of the company’s stock, valued at $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.